MAP2K7 and cancer: The mutation of components such as RAS, RAF and MEK results in dysregulation of the pathway in various types of cancer.111 Moreover, 30% of RAS GTPases are activated by mutations in these types of cancer, but inhibitors that directly target RAS proteins have not been developed.